Your browser doesn't support javascript.
loading
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study.
Klein, Kim; Beverloo, H Berna; Zimmermann, Martin; Raimondi, Susana C; von Neuhoff, Christine; de Haas, Valérie; van Weelderen, Romy; Cloos, Jacqueline; Abrahamsson, Jonas; Bertrand, Yves; Dworzak, Michael; Fynn, Alcira; Gibson, Brenda; Ha, Shau-Yin; Harrison, Christine J; Hasle, Henrik; Elitzur, Sarah; Leverger, Guy; Maschan, Alexei; Razzouk, Bassem; Reinhardt, Dirk; Rizzari, Carmelo; Smisek, Pter; Creutzig, Ursula; Kaspers, Gertjan J L.
Afiliação
  • Klein K; Pediatric Oncology, Cancer Center Amsterdam, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Beverloo HB; Department of Pediatric Hematology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Zimmermann M; Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • Raimondi SC; Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany.
  • von Neuhoff C; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • de Haas V; Department of Pediatric Hematology-Oncology, University Hospital Essen, Essen, Germany.
  • van Weelderen R; Clinical laboratory, Dutch Childhood Oncology Group, The Hague, The Netherlands.
  • Cloos J; Department of Pediatric Hematology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Abrahamsson J; Pediatric Oncology, Cancer Center Amsterdam, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Bertrand Y; Department of Pediatric Hematology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Dworzak M; Pediatric Oncology, Cancer Center Amsterdam, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Fynn A; Department of Pediatrics, Queen Silvia Children's Hospital, Gothenburg, Sweden.
  • Gibson B; Children's Leukemia Cooperative Group/European Organisation for Research and Treatment of Cancer, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France.
  • Ha SY; St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria.
  • Harrison CJ; Grupo Argentino de Tratamiento de la Leucemia Aguda, Children's Hospital La Plata, La Plata, Buenos Aires, Argentina.
  • Hasle H; Department of Paediatric Haematology, United Kingdom Childhood Leukaemia Study Group, Royal Hospital for Children, Glasgow, UK.
  • Elitzur S; Department of Pediatrics/Pediatric oncology, Hong Kong Children's Hospital, Hong Kong, China.
  • Leverger G; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.
  • Maschan A; Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark.
  • Razzouk B; Schneider Children's Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Reinhardt D; Hematopathology Department, Assistance Publique Hopitaux de Paris, Paris, France.
  • Rizzari C; Oncology and Immunology, Dmitriy Rogachev Federal Center for Pediatric Hematology, Moscow, Russia.
  • Smisek P; Children's Center for Cancer and Blood Diseases, Peyton Manning Children's Hospital at St. Vincent, Indianapolis, Indiana, USA.
  • Creutzig U; Department of Pediatric Hematology-Oncology, University Hospital Essen, Essen, Germany.
  • Kaspers GJL; Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, S. Gerardo Hospital, Monza, Italy.
Pediatr Blood Cancer ; 69(1): e29341, 2022 01.
Article em En | MEDLINE | ID: mdl-34532968
BACKGROUND: In addition to treatment response, cytogenetic and molecular aberrations are the most important prognostic factors in children with de novo acute myeloid leukemia (AML). However, little is known about cytogenetics at the time of relapse. METHODS: This international study analyzed the prognostic value of cytogenetic profiles and karyotypic changes in pediatric relapsed AML in relation to the probability of event-free (pEFS) and overall survival (pOS). For this purpose, cytogenetic reports from all patients registered on the Relapsed AML 2001/01 Study were reviewed and classified. RESULTS: Cytogenetic information at relapse was available for 403 (71%) of 569 registered patients. Frequently detected aberrations at relapse were t(8;21)(q22;q22) (n = 60) and inv(16)(p13.1q22)/t(16;16)(p13.1;q22) (n = 24), both associated with relatively good outcome (4-year pOS 59% and 71%, respectively). Monosomy 7/7q-, t(9;11)(p22;q23), t(10;11)(p12;q23), and complex karyotypes were associated with poor outcomes (4-year pOS 17%, 19%, 22%, and 22%, respectively). Of 261 (65%) patients for whom cytogenetic data were reliable at both diagnosis and relapse, pEFS was inferior for patients with karyotypic instability (n = 128, 49%), but pOS was similar. Unstable karyotypes with both gain and loss of aberrations were associated with inferior outcome. Early treatment response, time to relapse, and cytogenetic profile at time of relapse were the most important prognostic factors, both outweighing karytoypic instability per se. CONCLUSION: The cytogenetic subgroup at relapse is an independent risk factor for (event-free) survival. Cytogenetic assessment at the time of relapse is of high importance and may contribute to improved risk-adapted treatment for children with relapsed AML.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Aberrações Cromossômicas Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Revista: Pediatr Blood Cancer Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Aberrações Cromossômicas Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Revista: Pediatr Blood Cancer Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos